PARP antibody | knockout validation | Trevigen 4338-MC-50

This is a knockout-validated antibody summary, based on the publication "PARP1 depletion induces RIG-I-dependent signaling in human cancer cells", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

PARP antibody | knockout validation | Trevigen 4338-MC-50 figure 1
Figure 1. Western blot screening of PARP1 single cell-derived HCT116 subclones. Red asterisks mark PARP1 “knockout” (KO) clones. EV, extracts from HCT116 cells transfected with an “empty vector”. Extracts from Parp1-/- B cells were included as a negative control. From [1].
Antibody information

Mouse monoclonal IgG1

Company: Trevigen

Antibody: PARP

Catalog number: 4338-MC-50

Summary: Mouse monoclonal IgG1 against calf thymus PARP-1. Reacts with human, monkey, hamster, rat and mouse but not chicken. Suitable for western blot and immunocytochemistry.

Validation Method

Western blot

Sample

Control and PARP1 KO HCT116 and B cells. Cells were resuspended in RIPA buffer supplemented with PMSF, protease inhibitors and the phosphatase inhibitors sodium fluoride, sodium orthovanadate and β-glycerophosphate.

Secondary incubation

HRP-linked anti-mouse (Cell Signaling; 7076).

Clone note

The same clone (C2-10) is sold as Santa Cruz Biotechnology sc-53643; Enzo Life Sciences BML-SA249-0050, BML-SA250-0050; R&D Systems 4338-MC-50; Invitrogen MA3-950; Trevigen 4338-MC-50; BD Biosciences 556362.

References
  1. Ghosh R, Roy S, Franco S. PARP1 depletion induces RIG-I-dependent signaling in human cancer cells. PLoS ONE. 2018;13:e0194611 pubmed publisher